Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From Krka Group

Krka’s EBITDA Margin Slumps Despite Record H1 Sales

Krka has explained a near double-digit percentage point drop for its EBITDA margin, as it presented preliminary results for the first half of 2022.

Sales & Earnings Commercial

Krka Keeps Focus On Russia-Ukraine As Sales Climb 9%

Slovenia’s Krka surprised the market with nearly 10% group turnover growth in the first quarter, driven by increases in all six of its sales regions, “most key markets, and by all product and service groups.”

Sales & Earnings Strategy

Krka Spells Out Chinese Potential With Plans To Double Portfolio In 2022

Alongside discussing the firm’s preliminary financial results for 2021, Krka management explained how the company planned to make further inroads in China in 2022 and return to its 2020 revenue baseline in West Europe, following a dip last year.

Sales & Earnings Strategy

Krka Delivers On Pledge To Publish Five-Year Business Plan

Slovenian firm Krka wishes to strengthen and optimize its vertically integrated business model over the next five years, just one of many goals just published by the company under a new business plan to 2026.

Strategy Sales & Earnings
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Krka DD, Krka d.d., Krka Pharmaceuticals